Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis

Journal of Hepatology

Volumn 48, Issue SUPPL. 1, 2008, Pages

  Angeli, Paolo ^a   Merkel, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Human albumin; Renal failure; Terlipressin; Vasoconstrictors

Indexed keywords

ALBUMIN; HUMAN ALBUMIN; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; TERLIPRESSIN;

CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; PROGNOSIS;

EID: 40849104739     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.010     Document Type: Review

References (98)

1. Helvig F.C., and Schutz C.B. A liver and kidney syndrome: clinical, pathological, and experimental studies. Surg Gynecol Obstet 55 (1932) 570-582
2. Hecker R., and Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 2 (1956) 1121-1129
3. Papper S. The hepato-renal syndrome. Clin Nephrol 4 (1975) 41-54
4. Koppel M.H., Coburn J.W., Mims M.M., Goldstein H., Boyle J.D., and Rubini M.E. Transplantation of cadaveric kidneys from patients with hepato-renal syndrome: evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 280 (1969) 1367-1371
5. Epstein M., Berk D.P., Hollenberg N.K., Adams D.F., Chalmers T.C., Abrams H.L., et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49 (1970) 175-185
6. Arroyo V., Gines P., Gerbes A.L., Dudley F.J., Gentilini P., Laffi G., et al. Definition and diagnostic criteria of refractory ascites and hepato-renal syndrome in cirrhosis. Hepatology 23 (1996) 164-176
7. Salerno F., Gerbes A., Gines P., Wong F., and Arroyo V. Diagnosis, prevention and treatment of the hepato-renal syndrome in cirrhosis. Gut 56 (2007) 1310-1318
8. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608
9. Moreau R., and Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 37 (2003) 233-243
10. Gines A., Escorsell A., Gines P., Salo J., Jimenez W., Inglada L., et al. Incidence, predictive factors and prognosis of the hepato-renal syndrome in cirrhosis with ascites. Gastroenterology 105 (1993) 229-236
11. Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henriksen J.H., and Rodes J. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988) 1151-1157
12. Gines P., Guevara M., Arroyo V., and Rodes J. Hepato-renal syndrome. Lancet 362 (2003) 1819-1827
13. Follo A., Llovet J.M., Navasa M., Planas R., Forns X., Francitorra A., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20 (1994) 1495-1501
14. Angeli P., Guarda S., Fasolato S., Miola E., Craighero R., Piccolo F., et al. Switch therapy with ciprofloxacin versus intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis:similar efficacy at lower cost. Alimentary Pharmacol Ther 23 (2006) 75-84
15. Fasolato S., Angeli P., Dallagnese L., Maresio G., Zola E., Mazza E., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45 (2007) 223-229
16. Terra C., Guevara M., Torre A., Gilabert R., Fernandez J., Martin-Llahi M., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 129 (2005) 1944-1953
17. Arroyo V., Planas R., Gaya J., Deulofeu J., Rimola A., Perez-Ayuso R.M., et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 13 (1983) 271-278
18. Henriksen J.H., and Ring-Larsen H. Hepato-renal disorders: role of the sympathetic nervous system. Sem Liver Dis 14 (1994) 35-43
19. Gentilini P., Romanelli R.G., La Villa G., Maggiore Q., Pesciullesi E., Cappelli G., et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 104 (1993) 588-594
20. Solis-Herruzo J.A., Duran A., Favela V., Castellano G., Madrid J.L., Munoz-Yague M.T., et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepato-renal syndrome. J Hepatol 5 (1987) 167-173
21. Piscaglia F., Zironi G., Gaiani S., Ferlito M., Rapezzi C., Siringo S., et al. Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. Eur J Gastroenterol Hepatol 9 (1997) 799-804
22. Fernandez-Seara J., Prieto J., Quiroga J., Zozaia J.M., Cobos M.A., Rodriguez-Eire J.L., et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 97 (1989) 1304-13012
23. Maroto A., Gines P., Arroyo V., Gines A., Salò J., Claria J., et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 17 (1993) 788-793
24. Sacerdoti D., Bolognesi M., Merkel C., Angeli P., and Gatta A. Renal vasoconstriction in cirrhosis evaluated by duplex ultrasonography. Hepatology 17 (1993) 219-224
25. Dillon J.F., Plevris J.N., Wong F.C., Chan K.H., Lo N.T., Miller J.D., et al. Middle cerebral artery blood flow velocity in patients with cirrhosis. Eur J Gastroenterol Hepatol 7 (1995) 1087-1091
26. Rivolta R., Maggi A., Cazzaniga M., Castagnone D., Panzeri A., Solenghi D., et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology 28 (1998) 1235-1240
27. Guevara M., Bru C., Gines P., Fernadez-Esparrach G., Sort P., Bataller R., et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 28 (1998) 39-44
28. Sugano S., Yamamoto K., Atobe T., Watanabe M., Vakui N., Iwasaki N., et al. Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo controlled evaluation. J Hepatol 34 (2001) 373-377
29. Moller S., and Henriksen J. The systemic circulation in cirrhosis. In: Gines P., Arroyo V., Rodes J., and Schrier R.W. (Eds). Ascites and renal dysfunction in liver disease. II ed. (2005), Blackwell Publ. 139-155
30. Luca A., Garcia-Pagan J.C., Feu F., Lopez-Talavera J.C., Fernandez M., Bru C., et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 21 (1995) 83-88
31. Carella M., Hunter J.O., Fazio S., Dela Piano C., and Bartoli G.C. Capillary blood flow in the skin of forearm in cirrhosis. Angiology 43 (1992) 969-974
32. Newby D.E., Jalan R., Masumori S., Hayes P.C., Boon N.A., and Webb D.J. Peripheral vascular tone in patients with cirrhosis: role of the rennin-angiotensin and sympathetic nervous systems. Cardiovasc Res 38 (1998) 223-228
33. Angeli P., Albino G., Carraro P., Dalla Pria M., Merkel C., Caregaro L., et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 23 (1996) 264-273
34. Wiest R., and Groszmann R.J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35 (2002) 478-491
35. Bolognesi M., Sacerdoti D., Piva A., Di Pascoli M., Zampieri F., Quarta S., et al. Carbon monoxide-mediated activation of large conductance calcium-activated potassium channels contributes to mesenteric vasodilation in cirrhotic rats. J Pharmacol Exp Ther 321 (2007) 187-194
36. Sieber C.C., Mosca P.G., and Groszmann R.J. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 262 (1992) G274-G277
37. Fernandez M., Garcia-Pagan J.C., and Casadevall M. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology 110 (1998) 1529-1535
38. Guevara M., Gines P., Jimenez W., Sort P., Fernandez-Esparrach G., Escorsell A., et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 114 (1998) 336-343
39. Ros J., Claria J., To-Figueras J., Planagumà A., Cejudo-Marti{dotless}̀n P., Fernandez-Varo G., et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122 (2002) 85-93
40. Angeli P., Fernandez-Varo G., Dalla Libera V., Fasolato S., Galioto A., Arroyo V., et al. The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver 29 (2005) 429-437
41. Angeli P., Volpin R., Piovan D., Bortoluzzi A., Craighero R., Bottaro S., et al. Acute effects of an oral administration of midodrine an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 28 (1998) 937-943
42. Tristani F.E., and Cohn J.N. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 46 (1967) 1894-1906
43. Lebrec D., Kotelanski B., and Cohn J.N. Splanchnic hemodynamic factors in cirrhosis with refractory ascites. J Lab Clin Med 93 (1979) 301-309
44. Henriksen J.H. Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis. Scand J Clin Invest 64 (2004) 523-534
45. Ruiz del Arbol L., Urman J., Fernandez J., Gonzalez M., Navasa M., Monescillo A., et al. Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38 (2003) 1210-1218
46. Ruiz del Arbol L., Monescillo A., Arocena C., Valer P., Gines P., Moreira V., et al. Circulatory function and hepato-renal syndrome. Hepatology 42 (2005) 439-447
47. Tsai M.H., Peng Y.S., Chen Y.C., Liu N.I., Ho Y.P., Fang J.T., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 43 (2006) 673-681
48. Fernandez J., Escorsell A., Zabalza M., Felipe V., Navasa M., Mas A., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 44 (2006) 1288-1295
49. Ma Z.H., and Lee S.S. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24 (1996) 451-459
50. Bresing K.A., Textor J., Perez J., Schidermeier P., Raab P., Strunk H., et al. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepato-renal syndrome: a phase II study. Gut 47 (2000) 288-295
51. Soper C.P.R., Latif A.B., and Bendino M.R. Amelioration of hepato-renal syndrome with selective endothelin-A antagonist. Lancet 347 (1996) 1842-1843
52. Wong F., Moore K., Dingemanse J., and Jalan R. Lack of renal improvement with non selective endothelin antagonism with tezosentan in type 2 hepato-renal syndrome. Hepatology 47 (2008) 160-168
53. Rimola A., Gines P., Arroyo V., Camps J., Perez-Ayuso R.M., Quintero E., et al. Urinary excretion of 6-keto-prostaglandin F1α, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. J Hepatol 3 (1986) 111-117
54. Zipster R.D., Radvan G.H., Kronborg I.J., Duke R., and Little T.E. Urinary thromboxane B2 and prostaglandin E2 in the hepato-renal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 84 (1983) 697-703
55. Moore K.P., Taylor G.W., Maltby N.H., Siegers D., Fuller R.W., Dollerty C.T., et al. Increased production of cysteinyl leukotrienes in hepato-renal syndrome. J Hepatol 11 (1990) 263-271
56. Sacerdoti D., Balazy M., Angeli P., Gatta A., and McGiff J.C. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest 100 (1997) 1264-1270
57. Ros J., Claria J., Jimenez W., Bosch-Marcè M., Angeli P., Arroyo V., et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 22 (1995) 915-920
58. Angeli P., Jimenez W., Arroyo V., Mackenzie H.S., Zang P.L., Clari{dotless}̀a J., et al. Renal effects of endogenous natriuretic peptides receptors blockade in cirrhotic rats with ascites. Hepatology 20 (1994) 948-954
59. Laffi G., Daskalopoulos G., Kronborg I., Hsueh W., Gentilini P., and Ziepser R.D. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology 90 (1986) 182-187
60. Gonwa T.A., Klintmalm G.B., Levy M., Jennings L.S., Goldstein R.M., and Husberg B.S. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59 (1995) 361-365
61. Navasa M., Feu F., Garcia-Pagan J.C., Jimenez W., Llach J., Rimola A., et al. Hemodynamic and humoral changes after liver-transplantation in patients with cirrhosis. Hepatology 17 (1993) 355-360
62. Schlitt H.J., Barkmann A., Boeker K.H., Schmidt H.H., Enmanoulidis N., Rosenau J., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357 (2001) 587-591
63. Restuccia T., Ortega R., Guevara M., Gines P., Alessandria C., Ozdogan O., et al. Effects of treatment of hepato-renal syndrome before transplantation on posttransplantation outcome. A case control study. Liver Transpl 40 (2004) 140-146
64. Guevara M., Gines P., Bandi J.C., Gilabert R., Sort P., Jiménez W., et al. Transjugular intrahepatic portosystemic shunt in hepato-renal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
65. Guevara M., Gines P., Fernandez-Esparrach G., Sort P., Salmeron J.M., Jimenez W., et al. Reversibility of hepato-renal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 27 (1998) 35-41
66. Gilberg V., Bilzer M., and Gerbes A.L. Long-term therapy and retreatment of hepato-renal syndrome type 1 with ornipressin and albumin. Hepatology 30 (1999) 870-875
67. Ganne-Carrie N., Hadegue A., Mathurin P., Durand F., Erlinger S., and Benhamou J.P. Hepato-renal syndrome: long-term treatment with terlipressin as bridge to liver transplantation. Dig Dis Sci 41 (1996) 1054-1056
68. Le Moine O., El Nawar A., Jagodzinski R., Burgeois N., Adler M., Gelin M., et al. Treatment with terlipressin as a bridge to transplantation in a patient with hepato-renal syndrome. Acta Gastroenterol Belg 61 (1998) 268-270
69. Duhamel C., Mauillon J., Berkelmans J., Bourienne A., and Tranvuez J.L. Hepato-renal syndrome in cirrhotic patients: terlipressin is a safe and efficient treatment; propranolol and digitalic treatment: precipitating and preventing factors?. Am J Gastroenterol 95 (2000) 2984-2985
70. Halimi C., Bonnard P., Bernard B., Mathurin P., Mofredj A., di Martino V., et al. Effect of terlipressin (glypressin) on hepato-renal syndrome in cirrhotic patients: results of a multicenter pilot study. Eur J Gastroenterol Hepatol 14 (2002) 153-158
71. Mulkay J.P., Louis H., Donckier V., Burgeois N., Adler M., Deviere J., et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepato-renal syndrome: a pilot study. Acta Gastroelerologica Belg 64 (2001) 15-19
72. Uriz J., Gines P., Cardenas A., Sort P., Jimenez W., Salmeron J.M., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepato-renal syndrome. J Hepatol 33 (2000) 43-48
73. Ortega R., Gines P., Uriz J., Cardenas A., Calahorra B., De Las Heras D., et al. Terlipressin therapy with and without albumin for patients with hepato-renal syndrome: results of a prospective, nonrandomized study. Hepatology 36 (2002) 941-948
74. Solanki P., Chawala A., Garg R., Gupta R., Jain M., and Sarin S.K. Beneficial effects of terlipressin in hepato-renal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18 (2003) 152-156
75. Moreau R., Durand F., Poynard T., Duhamel C., Cervoni J.P., Ichai P., et al. Terlipressin in patients with cirrhosis and type 1 hepato-renal syndrome: a retrospective multicenter study. Gastroenterology 122 (2002) 923-930
76. Angeli P., Volpin R., Gerunda G., Craighero R., Roner P., Merenda R., et al. Reversal of type 1 hepato-renal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 29 (1999) 1690-1697
77. Colle I., Durand F., Pessione F., Rassiat E., Bernuau J., Barriere E., et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepato-renal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 17 (2002) 882-888
78. Wong F., Pantea L., and Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepato-renal syndrome. Hepatology 40 (2004) 55-64
79. Esrailian E., Pantageo E.R., Kyulo N.L., Hu K.Q., and Runyon B.A. Octretide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepato-renal syndrome. Dig Dis Sci 52 (2007) 742-748
80. Duvoux C., Zanditenas D., Hezode C., Chauvat A., Monin J.L., Roudot-Thoraval F., et al. Effects of noradrenalin and albumin in patients with type 1 hepato-renal syndrome: a pilot study. Hepatology 36 (2002) 374-380
81. Arroyo V., Terra C., and Gines P. Advances in the pathogenesis and treatment of type 1 and type 2 hepato-renal syndrome. J Hepatol 46 (2007) 935-936
82. Sanyal A., Boyer T., Garcia-Tsao G., Regenstein F., Rossaro L., Teuber P., et al. A prospective randomized double blind placebo-controlled trial of terlipressin for Type 1 hepato-renal syndrome (HRS). Hepatology 44 (2006) 494A
83. Martin-Llahi M., Pepin M.N., Guevara M., Torre A., Monescillo A., Soriano G., et al. Randomized comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepato-renal syndrome. J Hepatol 46 (2007) S36
84. Mitzner S.R., Stange J., Klammt S., Risler T., Erley C.M., Bader B.D., et al. Improvement of hepato-renal syndrome with extracorporeal albumin dialysis MARS: results on a prospective, randomized controlled clinical trial. Liver Transpl 6 (2000) 277-286
85. Angeli P. Review article: prognosis of hepato-renal syndrome - has it changed with current practice?. Aliment Pharmacol Ther 20 (2004) 1-4
86. Lebrec D., Giuily N., Hadengue A., Vilgrain V., Moreau R., Poynard T., et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites. J Hepatol 25 (1996) 135-144
87. Rossle M., Ochs A., Gulberg V., Siegerstetter V., Holl J., Deibert P., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Eng J Med 342 (2000) 1700-1707
88. Gines P., Uriz J., Calahorra B., Garcia-Tsao G., Kamath P.S., Ruiz del Arbol L., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123 (2002) 1839-1847
89. Sanyal A.J., Genning C., Reddy K.R., Wong F., Kowdley K.V., Benner K., et al. The North American Study for the treatment of refractory ascites. Gastroenterology 124 (2003) 634-641
90. Salerno F., Merli M., Riggio O., Cazzaniga M., Valeriano V., Pozzi M., et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40 (2004) 629-635
91. Saab S., Nieto J.M., Ly D., and Runyon B.A. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 3 (2004) CD004889
92. D'Amico G., Luca A., Morabito A., Miraglia R., and D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 129 (2005) 1282-1293
93. Salerno F., Cammà C., Enea M., Rossle M., and Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133 (2007) 825-834
94. Alessandria C., Venon W.D., Marzano A., Barletti C., Fadda M., and Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepato-renal syndrome type 2. Eur J Gastroenterol Hepatol 14 (2002) 1363-1368
95. Fernandez J., Navasa M., Planas R., Montoliu S., Monfort D., Soriano G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepato-renal syndrome and improves survival in cirrhosis. Gastroenterology 133 (2007) 818-824
96. Sort P., Navasa M., Arroyo V., Aldeguer X., Planas R., Ruiz del Arbol L., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
97. Fernandez J., Navasa M., Garcia-Pagan J.C., Abraldes J., Jimenez W., Bosch J., et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 41 (2004) 384-390
98. Evans T.W. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 16 (2002) 6-11